RCUS COO exercised options and sold 50,292 shares under 10b5-1
Rhea-AI Filing Summary
Insider transactions by Arcus Biosciences (RCUS): The company's Chief Operating Officer exercised stock options and sold a total of 50,292 shares across two dates, 10/06/2025 and 10/08/2025. The exercises used options with a $1.2276 exercise price, adding 50,292 underlying shares to the reporting pool. Sales were executed at weighted-average prices of $14.5441 and $15.0458, and the filings state these transactions were made pursuant to a Rule 10b5-1 trading plan. Following the transactions the reporting person beneficially owned 214,232 shares, which includes 863 shares bought via the employee stock purchase plan on 05/30/2025. The options exercised were fully vested and exercisable, with expiration dates noted as 03/14/2027.
Positive
- Transactions executed under a Rule 10b5-1 plan, indicating a pre-established trading arrangement
- Options were fully vested and exercisable, so exercises did not accelerate vesting
Negative
- Total of 50,292 shares sold, reducing direct beneficial ownership to 214,232 shares
- Sales occurred at market prices (weighted averages $14.5441 and $15.0458), which may be viewed unfavorably by some investors
Insights
TL;DR: Officer exercised vested options then sold shares under a Rule 10b5-1 plan, reducing direct holdings to 214,232 shares.
Mechanics: The reporting person exercised stock options with a $1.2276 exercise price on 10/06/2025 and 10/08/2025
The exercised shares (total 50,292) were immediately sold at weighted-average prices of $14.5441 and $15.0458, with the filings stating the transactions were executed under a Rule 10b5-1 trading plan. The options are fully vested and expire on 03/14/2027.
Dependencies and near-term items: Because the sale was under a pre-established 10b5-1 plan, timing was planned rather than ad hoc; investors might monitor any future plan disclosures or subsequent Form 4 filings for changes in ownership or additional plan-based trades within the next 12–18 months.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 37,792 | $0.00 | -- |
| Exercise | Common Stock | 37,792 | $1.2276 | $46K |
| Sale | Common Stock | 37,792 | $15.0458 | $569K |
| Exercise | Stock Option (Right to Buy) | 12,500 | $0.00 | -- |
| Exercise | Common Stock | 12,500 | $1.2276 | $15K |
| Sale | Common Stock | 12,500 | $14.5441 | $182K |
Footnotes (1)
- The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Includes 863 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The option is fully vested and currently exercisable.
